TMDX Stock Recent News

In the closing of the recent trading day, TransMedics (TMDX) stood at $84.74, denoting a +0.69% change from the preceding trading day.

TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.

Whether you believe them or not, analyst ratings have long been a strong indicator of the stock price's direction. There is a direct correlation between how Wall Street analysts rate a stock and how it performs.

FY2023: TransMedics' revenues up 159%, profitability improves, breakeven could be on the horizon. Potential 2x top-line growth medium term in the U.S. alone. TransMedics' Organ Care System (OCS) could drive transplant volumes by expanding the donor pool through increased utilization of marginal (including DCD) organs. As the only FDA-approved multi-organ platform, TransMedics faces relatively limited competition at the moment and looks well positioned to establish a market leading position.

TransMedics Group is transforming the organ transplant landscape with its expansive transplant solutions. The company has a proven technology, FDA approved, making it a rare early commercial-stage investment opportunity. TransMedics has led to double-digit growth in liver, lung, and heart transplants in the U.S., with a market size of over $1.5 billion in 2023.

The stock market keeps reaching new heights, but you can still find terrific growth stocks trading for reasonable prices. PubMatic's supply-side advertising platform generates a strong profit, and it has room to grow.

ANDOVER, Mass. , Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.

TransMedics Group, Inc. (TMDX) Q4 2023 Earnings Call Transcript

TransMedics has a dominant market position in the organ transplant market due to its revolutionary Organ Care System product, which helps organs survive longer, enabling significantly greater reach. At 15x TTM P/S and 9x NTM P/S, TransMedics stock is expensive but somewhat justified due to its triple-digit revenue growth rate. TransMedics' valuation is in line with Swedish peer, Xvivo Perfusion AB, despite growing significantly faster.

TransMedics (TMDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.